Spectrum Acquire Rights To RenaZorb

Spectrum (SPPI) has acquired 100% rights to RenaZorb (RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.

The acquisition includes all uses and thus provides full rights and intellectual property for the asset. In consideration for the license, Spectrum will pay a total of $750,000 in restricted common stock, to Altair

Rajesh Shrotriya, chairman, president and CEO of Spectrum, said: “While focused on the oncology field, we remain opportunistic with our other value-driving assets such as RenaZorb, a drug candidate with the potential to reduce dosage burden for chronic kidney disease patients and enable more effective management of their disease. Having full rights to this selective and potent nanotechnology-based drug candidate will facilitate our development and partnering strategy for this asset.”